AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
Sanjay Sethi,1 Edward Kerwin,2 Henrik Watz,3 Gary T Ferguson,4 Robert M Mroz,5,6 Rosa Segarra,7 Eduard Molins,7 Diana Jarreta,7 Esther Garcia Gil7 1Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, SUNY, Buffalo, NY, USA; 2Clinical Research Institute, Medford, OR, USA; 3Pulmo...
Main Authors: | Sethi S, Kerwin E, Watz H, Ferguson GT, Mroz RM, Segarra R, Molins E, Jarreta D, Garcia Gil E |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-03-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/amplify-a-randomized-phase-iii-study-evaluating-the-efficacy-and-safet-peer-reviewed-article-COPD |
Similar Items
-
Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
by: Dave Singh, et al.
Published: (2017-05-01) -
New combinations in the treatment of COPD: rationale for aclidinium–formoterol
by: Incorvaia C, et al.
Published: (2016-02-01) -
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
by: D'Urzo AD, et al.
Published: (2019-02-01) -
ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
by: Watz H, et al.
Published: (2017-08-01) -
Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
by: Contoli M, et al.
Published: (2016-12-01)